JAMA: WHO study confirms that IL-6 inhibitors can reduce the risk of death in hospitalized patients with new coronary pneumonia

Excessive inflammation and elevated IL-6 levels caused by systemic inflammation and host immune response imbalance are related to the adverse clinical results of hospitalized patients with new coronary pneumonia , but the conclusions of several completed trials of IL-6 antagonists for the treatment of hospitalized patients with new coronary pneumonia are There are big differences.
Some studies believe that IL-6 inhibitors are beneficial to patients with new coronary pneumonia, and some trials have concluded that they are ineffective or even harmful
.

Recently, the WHO Rapid Covid-19 Therapy Evidence Evaluation Working Group conducted a systematic review and meta-study to investigate the impact of IL-6 inhibitors compared with placebo or conventional treatment on the 28-day mortality risk of hospitalized patients with new coronary pneumonia

Immune to New Coronary Pneumonia Recently, the WHO Rapid Covid-19 Therapy Evidence Evaluation Working Group conducted a systematic review and meta-study to examine the impact of IL-6 inhibitors compared with placebo or conventional treatment on the 28-day mortality risk of hospitalized patients with new coronary pneumonia Recently, the WHO Rapid Covid-19 Therapy Evidence Evaluation Working Group conducted a systematic review and meta-study to examine the impact of IL-6 inhibitors compared with placebo or conventional treatment on the 28-day mortality risk of hospitalized patients with new coronary pneumonia

Researchers collected relevant clinical trial data from October 2020 to January 2021.
During this period, a total of 27 related studies were included in this meta-analysis, and they were randomly divided into IL-6 inhibitors or control groups (placebo or conventional treatment) In addition to corticosteroids, the patient does not receive other immunotherapy drugs
.

The primary endpoint of the study was 28-day mortality

A total of 10930 patients participated in the study, with an average age of 61 years, of which 3560 were female patients
.

On day 28, 1407 died of 6449 patients in the IL-6 inhibitor group, and 1158 died of 4481 patients in the conventional treatment or placebo group (OR=0.

Compared with the control group, after tocilizumab treatment, the patient's 28-day mortality risk ratio was 0.

This meta-study confirmed that treatment with IL-6 inhibitors in hospitalized patients with new coronary pneumonia can reduce the 28-day risk of death
.

Inpatients with new coronary pneumonia treated with IL-6 inhibitors can reduce the 28-day risk of death
.

Inpatients with new coronary pneumonia treated with IL-6 inhibitors can reduce the 28-day risk of death

Original source:

The WHO Rapid Evidence Appraisal for COVID-19 Therapies (REACT) Working Group.

COVID-19 Association Between Administration of IL-6 Antagonists and Mortality Among Patients Hospitalized for COVID-19 A Meta-analysis.
JAMA is here to leave a message